摘要 |
The present invention relates to the use of HDAC inhibitors for the preparation of a pharmaceutical composition for the amelioration, treatment or prevention of malignancies related to ischemic events or brain damage, whereby said HDAC inhibitor is selected from the group consisting of SAHA, M344, MS-275, CBHA and SBHA and whereby said HDAC inhibitor is most preferably SAHA. |
申请人 |
FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBERG;BLUEMCKE, INGMAR;HAHNEN, ERIC;SIEBZEHNRUEBL, FLORIAN;BUSLEI, ROLF;EYUEPOGLU, ILKER, YASIN |
发明人 |
BLUEMCKE, INGMAR;HAHNEN, ERIC;SIEBZEHNRUEBL, FLORIAN;BUSLEI, ROLF;EYUEPOGLU, ILKER, YASIN |